Literature DB >> 15277439

Matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 and -2 in type 2 diabetes: effect of 1 year's cardiovascular risk reduction therapy.

Muzahir H Tayebjee1, H Sern Lim, Robert J MacFadyen, Gregory Y H Lip.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15277439     DOI： 10.2337/diacare.27.8.2049

Source DB:  PubMed          Journal:  Diabetes Care        ISSN： 0149-5992            Impact factor:   19.112


× No keyword cloud information.
  19 in total

1.  Matrix metalloproteinases and cardiovascular diseases.

Authors:  A Papazafiropoulou; N Tentolouris
Journal:  Hippokratia       Date:  2009-04       Impact factor: 0.471

2.  Environmental arsenic exposure and serum matrix metalloproteinase-9.

Authors:  Jefferey L Burgess; Margaret Kurzius-Spencer; Mary Kay O'Rourke; Sally R Littau; Jason Roberge; Maria Mercedes Meza-Montenegro; Luis Enrique Gutiérrez-Millán; Robin B Harris
Journal:  J Expo Sci Environ Epidemiol       Date:  2012-12-12       Impact factor: 5.563

3.  Diagnosis, prevention, and treatment of cardiovascular diseases in people with type 2 diabetes and prediabetes: a consensus statement jointly from the Japanese Circulation Society and the Japan Diabetes Society.

Authors:  Eiichi Araki; Atsushi Tanaka; Nobuya Inagaki; Hiroshi Ito; Kohjiro Ueki; Toyoaki Murohara; Kenjiro Imai; Masataka Sata; Takehiro Sugiyama; Hideki Ishii; Shunsuke Yamane; Takashi Kadowaki; Issei Komuro; Koichi Node
Journal:  Diabetol Int       Date:  2020-11-30

4.  ADAM17 cleaves the insulin receptor ectodomain on endothelial cells and causes vascular insulin resistance.

Authors:  Thaysa Ghiarone; Jorge A Castorena-Gonzalez; Christopher A Foote; Francisco I Ramirez-Perez; Larissa Ferreira-Santos; Francisco J Cabral-Amador; Roger de la Torre; Rama R Ganga; Andrew A Wheeler; Camila Manrique-Acevedo; Jaume Padilla; Luis A Martinez-Lemus
Journal:  Am J Physiol Heart Circ Physiol       Date:  2022-08-26       Impact factor: 5.125

Review 5.  The role of interleukin 18 in the pathogenesis of hypertension-induced vascular disease.

Authors:  Simon W Rabkin
Journal:  Nat Clin Pract Cardiovasc Med       Date:  2009-03

6.  Inhibition of transcriptional activity of c-JUN by SIRT1.

Authors:  Zhanguo Gao; Jianping Ye
Journal:  Biochem Biophys Res Commun       Date:  2008-09-26       Impact factor: 3.575

7.  Type II diabetes mellitus and cardiovascular risk factors: Current therapeutic approaches.

Authors:  Christos Kalofoutis; Christina Piperi; Anastasios Kalofoutis; Fred Harris; David Phoenix; Jaipaul Singh
Journal:  Exp Clin Cardiol       Date:  2007

8.  Blood-brain barrier disruption in humans is independently associated with increased matrix metalloproteinase-9.

Authors:  Taura L Barr; Lawrence L Latour; Kyung-Yul Lee; Timothy J Schaewe; Marie Luby; George S Chang; Ziad El-Zammar; Shaista Alam; John M Hallenbeck; Chelsea S Kidwell; Steven Warach
Journal:  Stroke       Date:  2009-12-24       Impact factor: 7.914

9.  17ß-estradiol antagonizes the down-regulation of ERα/NOS-3 signaling in vascular endothelial dysfunction of female diabetic rats.

Authors:  Yi Han; Xiaozhen Li; Suming Zhou; Guoliang Meng; Yujiao Xiao; Wen Zhang; Zhuoying Wang; Liping Xie; Zhen Liu; Hui Lu; Yong Ji
Journal:  PLoS One       Date:  2012-11-29       Impact factor: 3.240

Review 10.  Neuroprotection for ischemic stroke: moving past shortcomings and identifying promising directions.

Authors:  Ryan C Turner; Brandon Lucke-Wold; Noelle Lucke-Wold; Alisa S Elliott; Aric F Logsdon; Charles L Rosen; Jason D Huber
Journal:  Int J Mol Sci       Date:  2013-01-17       Impact factor: 5.923
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.